Widely used:Recently Viewed
Clear All
$39 Mln
--
36.17
102.37
-1.91
--
--
--
--
-800738
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Eyenovia (EYEN)
| -77.36 | -14.38 | -36.59 | -69.81 | -54.19 | -32.45 | -- |
|
BSE Sensex*
| 13.08 | -1.05 | 2.13 | 24.69 | 11.60 | 16.47 | 11.89 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|
|
Eyenovia (EYEN)
| 27.61 | -59.25 | -33.99 | 35.27 | 57.19 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
$38.82 Mln
$0.03 Mln
$0.00 Mln
$2.30 Mln
$15.69 Mln
High
$0.37 - 2.57
76,909,400
NASDAQ: EYEN
New York, NY
https://www.eyenovia.com
Eyenovia, Inc., a commercial-stage ophthalmic pharmaceutical technology company, engages in developing a pipeline of microdose array print therapeutics. It focuses on commercializing Mydcombi (tropicamide and phenylephrine HCL ophthalmic spray) for... inducing mydriasis for routine diagnostic procedures and in conditions where short term pupil dilation is desired, and clobetasol propionate ophthalmic suspension for the treatment of post-operative pain and inflammation following ocular surgery. The company is also developing the Optejet delivery system for use in combination with its drug-device therapeutic programs and for out-licensing for use in combination with therapeutics for additional indications. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company has agreement with Formosa Pharmaceuticals. Inc. for Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York. Address: 295 Madison Avenue, New York, NY, United States, 10017 Read more
The total asset value of Eyenovia Inc (EYEN) stood at $ 34 Mln as on 30-Jun-24
The share price of Eyenovia Inc (EYEN) is $0.47 (NASDAQ) as of 03-Oct-2024 16:00 EDT. Eyenovia Inc (EYEN) has given a return of -54.19% in the last 3 years.
Eyenovia Inc (EYEN) has a market capitalisation of $ 39 Mln as on 02-Oct-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Eyenovia Inc (EYEN) is 36.17 times as on 02-Oct-2024, a 643% premium to its peers’ median range of 4.87 times.
Since, TTM earnings of Eyenovia Inc (EYEN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Eyenovia Inc (EYEN) and enter the required number of quantities and click on buy to purchase the shares of Eyenovia Inc (EYEN).
Eyenovia, Inc., a commercial-stage ophthalmic pharmaceutical technology company, engages in developing a pipeline of microdose array print therapeutics. It focuses on commercializing Mydcombi (tropicamide and phenylephrine HCL ophthalmic spray) for inducing mydriasis for routine diagnostic procedures and in conditions where short term pupil dilation is desired, and clobetasol propionate ophthalmic suspension for the treatment of post-operative pain and inflammation following ocular surgery. The company is also developing the Optejet delivery system for use in combination with its drug-device therapeutic programs and for out-licensing for use in combination with therapeutics for additional indications. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company has agreement with Formosa Pharmaceuticals. Inc. for Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York. Address: 295 Madison Avenue, New York, NY, United States, 10017
The CEO & director of Dr. Tsontcho Ianchulev M.D., M.P.H., MPH. is Eyenovia Inc (EYEN), and CFO & Sr. VP is Dr. Tsontcho Ianchulev M.D., M.P.H., MPH.
There is no promoter pledging in Eyenovia Inc (EYEN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
870
|
|
|
675
|
|
|
666
|
|
|
543
|
| Eyenovia Inc. (EYEN) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-99970.44
|
|
Net Margin(%)
|
-118712.53
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Eyenovia Inc (EYEN) was $0 Mln.
$-0.01
